The “Medical Bypass”: new drugs to strike obesity
Pharmaceutical Technology
NOVEMBER 30, 2022
In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Insurance may not cover these without showing clinical event reductions, and I am concerned that it may take five to 10 years to show this for just obesity,” Lavie added. Please check your email to download the Report.
Let's personalize your content